Another Cut for Valeant Pharmaceuticals Intl Inc.

With another disappointing earnings release, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may be yet another case of death by a thousand cuts.

| More on:
The Motley Fool

With another earnings release in the rear-view mirror, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have declined once again, this time to under $18 per share. The question is not if the company will go under (or be sold off into tiny pieces), but when will it happen.

The company was in positive cash flow territory, but the reality is the loss still amounts to $1.47 per share, making things even worse from last year’s loss of $1.04 per share. Cash flow from operations (CFO) was $2.087 for the year, but it decreased by $170 million from the previous year.

Although certain costs can be contained, it is extremely difficult for a company to hide the bad news with declining revenues. For fiscal 2016, revenues declined by approximately 7.4%, while the debt saga continued. For a large number of pharmaceutical companies, the percentage of revenues going to fund R&D and interest expenses combined is often upwards of 15%, but in the case of Valeant, the reality is that 2016 interest expenses alone were closer to 18%. In 2015, interest expenses accounted for a reasonable 12%.

Although management has pounded the table about paying down an additional $5 billion in debt, only $1 billion has been repaid so far. As of December 31, 2016, the company had debt on the balance sheet close to $30 billion. Assuming the company is successful in paying down the $5 billion, another $25 billion will still remain. If Valeant cuts 2016 interest expenses by 17% (one-sixth), the total interest expense would work out to approximately $1.43 billion, or 14.8%, of 2016 revenues.

Although this may seem reasonable to long investors, there are a few things we must remember. First, the company must repeat 2016 revenues, which is not a sure thing given the sell-off of several drugs over the past few months. The potential for revenues to decline still wouldn’t solve the interest expense problem, even after paying off $5 billion of debt.

The second and more important thing to consider is the mix of interest expense vs. R&D when looking at this 15% metric. When a company invests a portion of their revenues in R&D, it is a sign of things to come. New drugs are being developed and moving through the pipeline. Although not all of these drugs will be profitable, the ones which generate positive cash flows will most often cover those which do not become profitable.

Looking at the situation of Valeant, however, the red flags go up in conjunction with the ringing of a bell. If the entire 15% of revenues is going to interest expenses and none is going to R&D, then the question becomes, “what’s in the pipeline?” Clearly, without new cash-generating drugs under development, the company is taking 15% of revenues to pay off what was already purchased. The long-term survival of this company may be in jeopardy.

This may take a long time to play out. Be very careful on this one!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Goldsman has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »